Dexcom has launched its ONE+ continuous glucose monitoring (CGM) device in the UK, alongside a report that details high rates of anxiety and depression amongst type 2 diabetes (T2D) patients.
The Dexcom ONE+ device has already been launched in some European countries and can be worn on the abdomen, back of upper arms, or upper buttocks in children aged 2-17 years. It consists of a waterproof sensor that measures blood glucose, a transmitter that sends CGM readings and a Dexcom One smartphone-compatible app.
The system allows for real-time monitoring of blood glucose by both the user and up to ten additional people to allow for shared monitoring. The Dexcom ONE+ system features a one-touch sensor applicator, differing from Dexcom ONE which has a separate transmitter. It is 60% smaller than the ONE device.
Dexcom also released its State of Type 2 report which shows that 42% of diabetes patients and caregivers say T2D has harmed their mental health – 61% of those experiencing anxiety, and 52% suffering from depression.
However, the study also found that CGM usage amongst people with T2D can lead to greater user motivation and improved diabetes management. Out of the diabetes patients who suffer from negative mental health, 48% said being able to monitor their glucose levels would help them better manage the condition.
The advanced diabetes care devices market, including insulin pens, pumps, and CGM devices, is forecast to be worth $33.4bn in 2030, according to GlobalData’s Medical Intelligence Center.
Dexcom has gone from strength to strength in the UK, striking a deal with the National Health Service (NHS) in 2022 for CGM devices. This increased the Dexcom user base from 270,000 users at the end of 2017 to 1.7 million users globally at the end of 2022.
Last year, Dexcom was involved in a patent dispute with medical device giant Abbott over its G7 applicator for use with its CGM device. Abbott claimed patent infringement while Dexcom countered by seeking to invalidate Abbott’s patent for overextending its legal scope. Dexcom won the case in November 2023, maintaining Abbott’s patent as it stands.
UK Diabetes Psychology Network chair Rose Stewart said: “Many people living with T2D feel like they don’t understand their condition, and feel like it is beyond their control – this combination of issues can contribute to more problems managing diabetes and detrimental mental health challenges.
“Fortunately, with tech advancements, people living with T2D can now feel empowered to better understand their condition, feel like they can manage it effectively and live more confidently.”
